---
id: rubedo-alembic
slug: rubedo-alembic
entity_type: commercial
status: operational
data_completeness: very_high
last_researched: 2025-01-27
researcher: AI Assistant
version: 3.1
name: Rubedo Life Sciences
description: Biotechnology company developing senolytic therapies targeting senescent cells to treat chronic age-related diseases using AI-driven drug discovery platform ALEMBIC™
mission: To develop innovative therapies engineered to target cells which drive chronic age-related diseases. Rubedo Life Sciences uses its proprietary ALEMBIC™ AI-driven drug discovery platform to identify and selectively target pathological cells, such as senescent cells, which play a key role in the progression of various chronic disorders including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases.
entity_data:
  focus: Development of senolytic therapies targeting senescent cells to treat chronic age-related diseases using AI-driven drug discovery platform ALEMBIC™
  founded: 2018
  website: "https://www.rubedolife.com"
  industry: Biotechnology
  employees:
  note: Number not publicly disclosed
  as_of: 2024
  legal_name: Rubedo Life Sciences, Inc.
  european_operations:
  city: Milan
  address: Via Porlezza 12, Milan, 20123, Italy
  country: Italy
  purpose: European headquarters and clinical operations
  established: October 2024
taxonomy:
  geography: USA
  ai_technology:
  - Predictive ML/DL
  primary_focus:
  - AI-Driven Drug Discovery
  - Senescent Cells & Senolytics
  aging_approach:
  - Molecule Design
  - Senescent Cell Elimination
  - Therapeutic Development
  target_biology:
  - Cancer/Oncology
  - General Aging/Longevity
  development_stage: Clinical Trials
  therapeutic_modality:
  - Small Molecules
organizations:
  -
    name: SVAX
    role: partner
    org_type: company
    status: operational
    role_description: Strategic partner for clinical trials
    contribution_description: Strategic partnership to advance RLS-1946 through Phase 2 clinical trials in Saudi Arabia and Dubai
  -
    name: Rubedo Life Sciences
    role: primary
    org_type: company
    legal_name: Rubedo Life Sciences, Inc.
    founded: 2018
    website: "https://www.rubedolife.com"
    status: operational
    role_description: Primary organization
    contribution_description: Developer of ALEMBIC™ platform and senolytic therapies
  -
    name: Beiersdorf AG
    role: partner
    org_type: company
    status: operational
    role_description: Strategic partner
    contribution_description: Multi-year strategic partnership to develop innovative skin care products addressing cellular aging
products:
  -
    name: RLS-1496
    type: drug
    status: Phase 1 ongoing, Phase 1b/2a planned
    development_stage: Clinical Trials
  -
    name: RLS-1946
    type: drug
    status: Phase 2 planned
    development_stage: Research / Preclinical
  -
    name: ALEMBIC™
    type: platform
    status: Operational
    development_stage: Operational
links:
  -
    url: "https://practicaldermatology.com/news/ai-in-action-rubedo-life-sciences-introduces-rls-1496-as-a-potential-first-in-class-derm-drug/2461699/"
    type: article
    title: "AI in Action: Rubedo Life Sciences Introduces RLS-1496 as a Potential First-in-Class Derm Drug"
  -
    url: "https://www.pharmafocusamerica.com/pressreleases/rubedo-life-sciences-announces-clinical-development-plans"
    type: press_release
    title: Rubedo Life Sciences Announces Clinical Development Plans for Lead Candidate RLS-1496, a First-in-Class GPX4 Modulator Targeting Aging Cells and Surrounding Tissues
  -
    url: "https://www.nature.com/articles/s41593-025-01954-x"
    type: research_publication
    title: Aging and injury drive neuronal senescence in the dorsal root ganglia
  -
    url: "https://www.businesswire.com/news/home/20250522955270/en/Rubedo-Life-Sciences-Announces-First-Patient-Dosed-with-Lead-Drug-Candidate-RLS-1496-the-First-GPX4-Modulator-Targeting-Pathologic-Senescent-Cells-To-Enter-Phase-1-Clinical-Trial"
    type: press_release
    title: Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496
  -
    url: "https://www.rubedolife.com/science-platform/"
    type: website
    title: Rubedo Life Sciences - Science & Platform
  -
    url: "https://www.businesswire.com/news/home/20230503005464/en/Rubedo-Life-Sciences-Announces-Nomination-of-First-in-Class-Disease-Modifying-Candidate-RLS-1496-in-Dermatology-at-LSX-World-Congress-2023"
    type: press_release
    title: Rubedo Life Sciences Announces Nomination of First-in-Class Disease-Modifying Candidate RLS-1496 in Dermatology at LSX World Congress 2023
  -
    url: "https://www.sahmcapital.com/news/content/pressr-rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh-2025-11-01"
    type: press_release
    title: Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh
  -
    url: "https://www.pharmiweb.com/press-release/2022-08-01/rubedo-life-sciences-expands-leadership-team-with-ali-siam-as-chief-business-officer-and-ofir-moreno"
    type: press_release
    title: Rubedo Life Sciences Expands Leadership Team with Ali Siam as Chief Business Officer and Ofir Moreno
  -
    url: "https://www.businesswire.com/news/home/20230206005081/en/Rubedo-Life-Sciences-Awarded-%241.45M-in-Funding-From-the-California-Institute-for-Regenerative-Medicine-CIRM-for-Idiopathic-Pulmonary-Fibrosis-Program"
    type: press_release
    title: Rubedo Life Sciences Awarded $1.45M in Funding From the California Institute for Regenerative Medicine (CIRM) for Idiopathic Pulmonary Fibrosis Program
  -
    url: "https://www.biospace.com/press-releases/rubedo-life-sciences-announces-u-s-fda-clearance-of-ind-for-selective-gpx4-modulating-lead-drug-candidate-rls-1496-for-actinic-keratosis-expands-clinical-advisory-board"
    type: press_release
    title: Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis
  -
    url: "https://www.businesswire.com/news/home/20201203005330/en/Rubedo-Life-Sciences-Closes-%2412M-Seed-Financing-Led-by-Khosla-Ventures"
    type: press_release
    title: Rubedo Life Sciences Closes $12M Seed Financing Led by Khosla Ventures
  -
    url: "https://www.businesswire.com/news/home/20241023573741/en/Rubedo-Life-Sciences-Announces-European-Expansion-Ahead-of-First-Clinical-Trial"
    type: press_release
    title: Rubedo Life Sciences Announces European Expansion Ahead of First Clinical Trial
  -
    url: "https://www.businesswire.com/news/home/20240423657886/en/Rubedo-Life-Sciences-and-Beiersdorf-Announce-Multi-Year-Partnership-to-Pioneer-New-Skin-Care-Products-that-Address-Cellular-Aging"
    type: press_release
    title: Rubedo Life Sciences and Beiersdorf Announce Multi-Year Partnership to Pioneer New Skin Care Products that Address Cellular Aging
  -
    url: "https://www.businesswire.com/news/home/20240422384739/en/Rubedo-Life-Sciences-Closes-40M-Series-A-Financing-Led-by-Khosla-Ventures-and-Ahren-Innovation-Capital"
    type: press_release
    title: Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital
  -
    url: "https://www.businesswire.com/news/home/20250514558243/en/Rubedo-Life-Sciences-Drug-Discovery-Platform-ALEMBIC-Helps-Identify-Senescent-or-Zombie-Neurons-in-New-Study-Linking-Neuropathic-Pain-and-Aging-Published-in-Peer-Reviewed-Scientific-Journal-Nature-Neuroscience"
    type: press_release
    title: "Rubedo Life Sciences' Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or 'Zombie' Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience"
---

# Rubedo Life Sciences

## Description

Biotechnology company developing senolytic therapies targeting senescent cells to treat chronic age-related diseases using AI-driven drug discovery platform ALEMBIC™

## Mission

To develop innovative therapies engineered to target cells which drive chronic age-related diseases. Rubedo Life Sciences uses its proprietary ALEMBIC™ AI-driven drug discovery platform to identify and selectively target pathological cells, such as senescent cells, which play a key role in the progression of various chronic disorders including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases.

## Company Information

**Legal Name**: Rubedo Life Sciences, Inc.
**Founded**: 2018
**Industry**: Biotechnology
**Employees**: {"note":"Number not publicly disclosed","as_of":"2024"}
**Focus**: Development of senolytic therapies targeting senescent cells to treat chronic age-related diseases using AI-driven drug discovery platform ALEMBIC™
**Website**: https://www.rubedolife.com

## AI Methods

- Machine Learning
- Generative Chemistry
- Pattern Recognition
- Predictive ML/DL

## Data Types

- Single-cell RNA sequencing (scRNA-seq)
- Spatial multi-omics data
- Proteomics data
- Histopathology data

## Platforms

- ALEMBIC™

## Scientific Background

```yaml
gpx4_targeting:
  mechanism: Modulating GPX4 in senescent cells can selectively target these pathological cells while sparing healthy cells, offering a novel approach to senolytic therapy. This represents a departure from first-generation senolytics that targeted Bcl-xL or other apoptosis pathways.
  advantages: GPX4 modulation offers potential for greater selectivity compared to Bcl-xL inhibitors, as senescent cells may have unique GPX4 vulnerabilities that healthy cells lack.
  description: GPX4 (Glutathione Peroxidase 4) is a key enzyme in the antioxidant defense system that protects cells from ferroptosis, a form of iron-dependent cell death. Senescent cells may have altered GPX4 expression or activity, making them more vulnerable to GPX4 modulation.
alembic_platform:
  workflow:
  step1: Collection of clinical tissue samples from patients with age-related diseases
  step2: Single-cell RNA sequencing to generate high-resolution transcriptomic profiles
  step3: AI analysis to identify senescent cell populations and their unique molecular signatures
  step4: Identification of druggable targets unique to senescent cells
  step5: Generative chemistry and medicinal chemistry optimization to design selective compounds
  step6: Validation of selectivity and efficacy in preclinical models
  description: ALEMBIC™ (Algorithms for Life-Extending Medicine with Biology, Informatics, and Chemistry) is an AI-driven drug discovery platform that uses single-cell RNA sequencing (scRNA-seq) and spatial multi-omics data to identify and profile heterogeneous senescent and senescent-like cell populations in clinical samples from affected tissues.
  differentiators:
  - Uses clinical samples from patients rather than only cell culture models
  - Combines scRNA-seq with spatial multi-omics for tissue context
  - AI-driven target identification enables discovery of novel targets beyond obvious candidates
  - Proprietary chemistry process optimizes for selectivity and safety
  technology_stack:
  - Single-cell RNA sequencing (scRNA-seq) for high-resolution cell type identification
  - Spatial multi-omics analysis for tissue context
  - Machine learning algorithms for pattern recognition in omics data
  - Generative chemistry for molecule design
  - Proprietary medicinal chemistry process (SenTech) for compound optimization
selective_targeting: The ALEMBIC™ platform enables identification of druggable targets unique to senescent cells, allowing development of therapeutics that selectively eliminate pathological cells while minimizing off-target effects on healthy tissue. This addresses a key limitation of first-generation senolytics (like navitoclax and dasatinib) which were repurposed drugs with significant off-target effects.
senescence_mechanism: "Cellular senescence is a state in which cells stop dividing and enter a state of permanent growth arrest. Senescent cells accumulate with age and secrete pro-inflammatory factors (SASP - Senescence-Associated Secretory Phenotype) that contribute to age-related diseases. These 'zombie cells' can persist in tissues and drive chronic inflammation and tissue dysfunction."
comparison_with_first_generation:
  next_generation: RLS-1496 represents a next-generation approach, being specifically designed using AI to target senescent cells selectively. GPX4 modulation offers a novel mechanism distinct from Bcl-xL inhibition used by first-generation compounds.
  first_generation: First-generation senolytics (navitoclax, dasatinib, quercetin) were repurposed drugs not originally designed for senescent cells, leading to off-target effects and safety concerns.
```

## Lessons Learned

### Achievements

- Successfully developed ALEMBIC™ AI-driven platform for senolytic discovery
- Advanced RLS-1496 to Phase 1 clinical trials
- Established strategic partnerships with Beiersdorf AG and SVAX
- Published research in Nature Neuroscience demonstrating platform utility
- Raised $52 million in funding across Seed and Series A rounds

### Challenges

- Developing selective senolytics that target senescent cells without affecting healthy cells
- Identifying druggable targets unique to senescent cells in different tissue contexts
- Translating AI-driven platform discoveries into clinical candidates

### Impact on Field

Rubedo Life Sciences represents a next-generation approach to senolytic development, using AI to identify and selectively target senescent cells. The company's ALEMBIC™ platform enables discovery of novel targets and development of first-in-class therapeutics, potentially offering safer and more effective alternatives to first-generation senolytics that were repurposed drugs with off-target effects.

## Organizations

### SVAX
**Role in Project**: partner
**Role Description**: Strategic partner for clinical trials
**Contribution**: Strategic partnership to advance RLS-1946 through Phase 2 clinical trials in Saudi Arabia and Dubai
**Organization Type**: company
**Status**: operational
**Description**: Strategic partner of Rubedo Life Sciences for clinical trials in Saudi Arabia and Dubai
**Focus**: Clinical trials, Healthcare

### Rubedo Life Sciences
**Legal Name**: Rubedo Life Sciences, Inc.
**Role in Project**: primary
**Role Description**: Primary organization
**Contribution**: Developer of ALEMBIC™ platform and senolytic therapies
**Organization Type**: company
**Status**: operational
**Founded**: 2018
**Website**: https://www.rubedolife.com
**Description**: Biotechnology company developing senolytic therapies targeting senescent cells to treat chronic age-related diseases using AI-driven drug discovery platform ALEMBIC™
**Focus**: Development of senolytic therapies targeting senescent cells to treat chronic age-related diseases using AI-driven drug discovery platform ALEMBIC™

### Beiersdorf AG
**Role in Project**: partner
**Role Description**: Strategic partner
**Contribution**: Multi-year strategic partnership to develop innovative skin care products addressing cellular aging
**Organization Type**: company
**Status**: operational
**Description**: German multinational pharmaceutical and biotechnology company, strategic partner of Rubedo Life Sciences
**Focus**: Pharmaceuticals, Biotechnology, Skin care products

## Locations

### Rubedo Life Sciences European Headquarters
**Type**: office
**Address**: Via Porlezza 12, Milan, 20123, Italy
**City**: Milan
**Country**: Italy
**Organizations**: Rubedo Life Sciences

### Rubedo Life Sciences Headquarters
**Type**: headquarters
**Address**: 428 Oakmead Parkway, Sunnyvale, CA 94085, USA
**City**: Sunnyvale
**State/Region**: California
**Country**: USA
**Organizations**: Rubedo Life Sciences

## Products

### RLS-1496
**Type**: drug
**Status**: Phase 1 ongoing, Phase 1b/2a planned
**Development Stage**: Clinical Trials
**Role in Project**: primary
**Relationship Description**: Lead drug candidate for dermatological applications
**Description**: First-in-class GPX4 modulator designed to selectively target senescent cells and surrounding tissues
**Mechanism of Action**: First-in-class GPX4 modulator designed to selectively target senescent cells and surrounding tissues
**Target**: GPX4 (Glutathione Peroxidase 4)
**Pathway**: GPX4 pathway in senescent cells
**Capabilities**:
- Selective targeting of senescent cells
- Disease modification in chronic inflammatory conditions
- Reduction of senescence signatures
- Treatment of age-related dermatological diseases
**Applications**:
- Dermatology
- Chronic inflammatory skin conditions
- Age-related diseases
**Indications**: [
  {
    "primary": "Chronic Atopic Dermatitis",
    "secondary": "Chronic Psoriasis"
  }
]
**Clinical Trials**:
```yaml
-
  name: Phase 1 Safety and Efficacy Study
  phase: Phase 1
  design: Phase 1 clinical trial to evaluate safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496
  status: Ongoing
  results:
  summary: First patient dosed in May 2025. Trial ongoing. Results expected in Q4 2025.
  location: Netherlands, Europe
  endpoints:
  primary: Safety and tolerability
  secondary:
  - Cellular senescence biomarkers
  - Aging biomarkers
  - Clinical efficacy
  - Pharmacokinetics
  indication: Mild to moderate stable plaque psoriasis, skin aging, and other inflammatory conditions including atopic dermatitis, vitiligo, rosacea, alopecia, and scleroderma
  start_date: 2025-05-01
  first_patient_dosed: 2025-05-01
-
  name: Phase 1b/2a Study for Actinic Keratosis
  phase: Phase 1b/2a
  status: Planned
  results:
  summary: FDA cleared IND application. Trial planned to begin in Q4 2025.
  location: USA
  fda_status: IND cleared by FDA in September 2025
  indication: Actinic Keratosis
  start_date: 2025-10-01
  fda_clearance_date: 2025-09-01
```
**Technical Details**:
```yaml
notes: First-in-class disease-modifying candidate for dermatology. Nominated at LSX World Congress 2023. First patient dosed in Phase 1 trial in May 2025. FDA cleared IND for Phase 1b/2a study in actinic keratosis in September 2025. First GPX4 modulator to enter clinical trials targeting pathologic senescent cells.
preclinical_data:
  summary: Preclinical studies demonstrated that RLS-1496 significantly reduced senescence signatures associated with skin senescent cells in punch biopsies from skin lesions of patients with chronic atopic dermatitis and psoriasis
  histopathology: Histopathological assessment showed significant reduction in senescence markers in skin biopsies from patients with chronic atopic dermatitis and psoriasis
regulatory_status: IND cleared (Phase 1b/2a for actinic keratosis)
```

### RLS-1946
**Type**: drug
**Status**: Phase 2 planned
**Development Stage**: Research / Preclinical
**Role in Project**: primary
**Relationship Description**: Drug candidate for pulmonary diseases
**Description**: Senolytic candidate targeting senescent cells in pulmonary diseases
**Mechanism of Action**: Senolytic candidate targeting senescent cells in pulmonary diseases
**Target**: Senescent cells
**Pathway**: Senescence pathway
**Capabilities**:
- Selective targeting of senescent cells in pulmonary tissue
- Treatment of pulmonary fibrosis
- Disease modification in lung diseases
**Applications**:
- Pulmonology
- Lung fibrosis
- Chronic pulmonary diseases
**Indications**: [
  {
    "primary": "Idiopathic Pulmonary Fibrosis (IPF)",
    "secondary": "Chronic Obstructive Pulmonary Disease (COPD)"
  }
]
**Clinical Trials**:
```yaml
-
  name: Phase 2 Clinical Trial
  phase: Phase 2
  status: Planned
  results:
  summary: Trial planned in collaboration with SVAX
  location: Saudi Arabia and Dubai
  indication: Idiopathic Pulmonary Fibrosis
  start_date: 2025-11-01
```
**Technical Details**:
```yaml
notes: Pulmonary disease program candidate. Strategic partnership with SVAX announced in November 2025 for Phase 2 clinical trials in Saudi Arabia and Dubai.
regulatory_status: Pre-IND
```

### ALEMBIC™
**Alternative Names**: ALEMBIC, Algorithms for Life-Extending Medicine with Biology, Informatics, and Chemistry
**Type**: platform
**Status**: Operational
**Development Stage**: Operational
**Role in Project**: primary
**Relationship Description**: AI-driven drug discovery platform
**Description**: ALEMBIC™ (Algorithms for Life-Extending Medicine with Biology, Informatics, and Chemistry) is an AI-driven drug discovery platform that uses single-cell RNA sequencing (scRNA-seq) and spatial multi-omics data to identify and profile heterogeneous senescent and senescent-like cell populations in clinical samples from affected tissues.
**Capabilities**:
- Identification and profiling of senescent cell populations
- AI-driven target discovery
- Selective compound design
- Generative chemistry for molecule design
- Medicinal chemistry optimization
**Applications**:
- Drug discovery
- Senolytic therapy development
- Target identification
- Precision medicine
**Technical Details**:
```yaml
workflow:
  step1: Collection of clinical tissue samples from patients with age-related diseases
  step2: Single-cell RNA sequencing to generate high-resolution transcriptomic profiles
  step3: AI analysis to identify senescent cell populations and their unique molecular signatures
  step4: Identification of druggable targets unique to senescent cells
  step5: Generative chemistry and medicinal chemistry optimization to design selective compounds
  step6: Validation of selectivity and efficacy in preclinical models
ai_methods:
  - Machine Learning
  - Generative Chemistry
  - Pattern Recognition
data_types:
  - Single-cell RNA sequencing (scRNA-seq)
  - Spatial multi-omics data
  - Proteomics data
  - Histopathology data
ai_components:
  optimization: AI-guided medicinal chemistry optimization to improve drug-like properties
  molecule_design: Generative chemistry algorithms propose novel small molecule structures optimized for selectivity and safety
  target_discovery: AI identifies druggable targets unique to senescent cells by comparing molecular profiles of senescent vs healthy cells
  cell_identification: Machine learning algorithms analyze scRNA-seq data to identify and classify senescent cell populations based on transcriptomic signatures
differentiators:
  - Uses clinical samples from patients rather than only cell culture models
  - Combines scRNA-seq with spatial multi-omics for tissue context
  - AI-driven target identification enables discovery of novel targets beyond obvious candidates
  - Proprietary chemistry process optimizes for selectivity and safety
technology_stack:
  - Single-cell RNA sequencing (scRNA-seq) for high-resolution cell type identification
  - Spatial multi-omics analysis for tissue context
  - Machine learning algorithms for pattern recognition in omics data
  - Generative chemistry for molecule design
  - Proprietary medicinal chemistry process (SenTech) for compound optimization
validation_approach: Platform validated through identification of senescent neurons in Nature Neuroscience publication (May 2025), demonstrating utility in diverse tissue contexts beyond original dermatology focus.
```

## Key People

### Ofir Moreno
**Title**: PhD
**Participation Type**: leadership
**Role in Project**: SVP, Drug Discovery
**Biography**: SVP, Drug Discovery at Rubedo Life Sciences

### Judith Campisi
**Title**: PhD
**Participation Type**: advisor
**Role in Project**: Scientific Advisor
**Affiliations**: Buck Institute for Research on Aging
**Expertise**: Cellular senescence, aging research; Cellular senescence, aging research, cancer biology
**Biography**: Professor of Biogerontology at Buck Institute for Research on Aging. Renowned researcher in cellular senescence and its role in inflammation, cancer, and degenerative diseases. Pioneer in the field of senolytics. Scientific Advisor to Rubedo Life Sciences.

### Frederick Beddingfield III
**Title**: MD, PhD, FAAD, FACMS
**Participation Type**: leadership
**Role in Project**: CEO
**Participation Period**: 2024-present
**Expertise**: Dermatology, Medical aesthetics, Drug development
**Biography**: CEO of Rubedo Life Sciences. Former executive at Allergan, extensive experience in dermatology and medical aesthetics. Appointed CEO in 2024 to lead clinical development and commercialization efforts.

### Lidia Schapira
**Title**: MD
**Participation Type**: advisor
**Role in Project**: Scientific Advisor
**Affiliations**: Stanford University School of Medicine, Stanford Comprehensive Cancer Center
**Expertise**: Medical oncology, cancer survivorship, patient care
**Biography**: Professor of Medicine at Stanford University School of Medicine; Director of Cancer Survivorship Program, Stanford Comprehensive Cancer Center. Scientific Advisor to Rubedo Life Sciences.

### Ali Siam
**Participation Type**: leadership
**Role in Project**: Chief Business Officer
**Biography**: Chief Business Officer at Rubedo Life Sciences

### Emma Guttman-Yassky
**Title**: MD, PhD
**Participation Type**: advisor
**Role in Project**: Clinical Advisor
**Affiliations**: Icahn School of Medicine at Mount Sinai
**Involvement Period**: {"start":"2025-09-01","status":"active"}
**Expertise**: Dermatology, atopic dermatitis, inflammatory skin diseases
**Biography**: Professor and Chair, Department of Dermatology, Icahn School of Medicine at Mount Sinai. Leading expert in dermatology, particularly in atopic dermatitis and inflammatory skin conditions. Joined clinical advisory board in September 2025.

### Marco Quarta
**Title**: PhD
**Participation Type**: founder
**Role in Project**: Co-founder, Chief Scientific Officer
**Participation Period**: 2018-present
**Expertise**: Cellular senescence, aging research, drug discovery
**Biography**: Co-founder and Chief Scientific Officer of Rubedo Life Sciences. Previously at Stanford University, researcher in cellular senescence and aging.

## Links

### [AI in Action: Rubedo Life Sciences Introduces RLS-1496 as a Potential First-in-Class Derm Drug](https://practicaldermatology.com/news/ai-in-action-rubedo-life-sciences-introduces-rls-1496-as-a-potential-first-in-class-derm-drug/2461699/)
**Type**: article
**Relevance**: secondary
**Category**: reference
**Publication Date**: 2024-01-01
**Description**: Article describing ALEMBIC platform and RLS-1496 development

### [Rubedo Life Sciences Announces Clinical Development Plans for Lead Candidate RLS-1496, a First-in-Class GPX4 Modulator Targeting Aging Cells and Surrounding Tissues](https://www.pharmafocusamerica.com/pressreleases/rubedo-life-sciences-announces-clinical-development-plans)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2024-01-01
**Description**: Press release announcing clinical development plans for RLS-1496

### [Aging and injury drive neuronal senescence in the dorsal root ganglia](https://www.nature.com/articles/s41593-025-01954-x)
**Type**: research_publication
**Relevance**: primary
**Category**: publication
**Publication Date**: 2025-05-14
**Authors**: Donovan, L.J., Brewer, C.L., Bond, S.F., et al.
**Description**: Peer-reviewed scientific publication in Nature Neuroscience featuring research using Rubedo's ALEMBIC™ platform
**Metadata**:
```yaml
doi: 10.1038/s41593-025-01954-x
journal: Nature Neuroscience
company_contribution: ALEMBIC™ platform used to identify senescent neurons
```

### [Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496](https://www.businesswire.com/news/home/20250522955270/en/Rubedo-Life-Sciences-Announces-First-Patient-Dosed-with-Lead-Drug-Candidate-RLS-1496-the-First-GPX4-Modulator-Targeting-Pathologic-Senescent-Cells-To-Enter-Phase-1-Clinical-Trial)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-05-22
**Description**: Press release announcing first patient dosed in Phase 1 clinical trial

### [Rubedo Life Sciences - Science & Platform](https://www.rubedolife.com/science-platform/)
**Type**: website
**Relevance**: primary
**Category**: source
**Description**: Company website page describing ALEMBIC™ platform technology

### [Rubedo Life Sciences Announces Nomination of First-in-Class Disease-Modifying Candidate RLS-1496 in Dermatology at LSX World Congress 2023](https://www.businesswire.com/news/home/20230503005464/en/Rubedo-Life-Sciences-Announces-Nomination-of-First-in-Class-Disease-Modifying-Candidate-RLS-1496-in-Dermatology-at-LSX-World-Congress-2023)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2023-05-03
**Description**: Press release announcing RLS-1496 nomination at LSX World Congress

### [Rubedo Life Sciences and SVAX Announce Strategic Partnership During FII Week in Riyadh](https://www.sahmcapital.com/news/content/pressr-rubedo-life-sciences-and-svax-announce-strategic-partnership-during-fii-week-in-riyadh-2025-11-01)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-11-01
**Description**: Press release announcing strategic partnership with SVAX

### [Rubedo Life Sciences Expands Leadership Team with Ali Siam as Chief Business Officer and Ofir Moreno](https://www.pharmiweb.com/press-release/2022-08-01/rubedo-life-sciences-expands-leadership-team-with-ali-siam-as-chief-business-officer-and-ofir-moreno)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2022-08-01
**Description**: Press release about leadership team expansion

### [Rubedo Life Sciences Awarded $1.45M in Funding From the California Institute for Regenerative Medicine (CIRM) for Idiopathic Pulmonary Fibrosis Program](https://www.businesswire.com/news/home/20230206005081/en/Rubedo-Life-Sciences-Awarded-%241.45M-in-Funding-From-the-California-Institute-for-Regenerative-Medicine-CIRM-for-Idiopathic-Pulmonary-Fibrosis-Program)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2023-02-06
**Description**: Press release announcing CIRM grant for IPF program

### [Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis](https://www.biospace.com/press-releases/rubedo-life-sciences-announces-u-s-fda-clearance-of-ind-for-selective-gpx4-modulating-lead-drug-candidate-rls-1496-for-actinic-keratosis-expands-clinical-advisory-board)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-09-17
**Description**: Press release announcing FDA IND clearance for Phase 1b/2a study in actinic keratosis

### [Rubedo Life Sciences Closes $12M Seed Financing Led by Khosla Ventures](https://www.businesswire.com/news/home/20201203005330/en/Rubedo-Life-Sciences-Closes-%2412M-Seed-Financing-Led-by-Khosla-Ventures)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2020-12-03
**Description**: Press release announcing $12 million seed financing round

### [Rubedo Life Sciences Announces European Expansion Ahead of First Clinical Trial](https://www.businesswire.com/news/home/20241023573741/en/Rubedo-Life-Sciences-Announces-European-Expansion-Ahead-of-First-Clinical-Trial)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2024-10-23
**Description**: Press release announcing European expansion and Milan headquarters

### [Rubedo Life Sciences and Beiersdorf Announce Multi-Year Partnership to Pioneer New Skin Care Products that Address Cellular Aging](https://www.businesswire.com/news/home/20240423657886/en/Rubedo-Life-Sciences-and-Beiersdorf-Announce-Multi-Year-Partnership-to-Pioneer-New-Skin-Care-Products-that-Address-Cellular-Aging)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2024-04-23
**Description**: Press release announcing strategic partnership with Beiersdorf AG

### [Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital](https://www.businesswire.com/news/home/20240422384739/en/Rubedo-Life-Sciences-Closes-40M-Series-A-Financing-Led-by-Khosla-Ventures-and-Ahren-Innovation-Capital)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2024-04-22
**Description**: Press release announcing $40 million Series A financing round

### [Rubedo Life Sciences' Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or 'Zombie' Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience](https://www.businesswire.com/news/home/20250514558243/en/Rubedo-Life-Sciences-Drug-Discovery-Platform-ALEMBIC-Helps-Identify-Senescent-or-Zombie-Neurons-in-New-Study-Linking-Neuropathic-Pain-and-Aging-Published-in-Peer-Reviewed-Scientific-Journal-Nature-Neuroscience)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publication Date**: 2025-05-14
**Description**: Press release about Nature Neuroscience publication featuring ALEMBIC™ platform
**Metadata**:
```yaml
platform: ALEMBIC™
related_publication: Nature Neuroscience
```

## Financials

### grant
**Amount**: $1.45 million USD
**Amount (Numeric)**: 1450000
**Funding Date**: 2023-02-06
**Source**: California Institute for Regenerative Medicine (CIRM)
**Funding Type**: Grant
**Description**: Grant for pharmacological regenerative treatment for Idiopathic Pulmonary Fibrosis (IPF) targeting senescent lung stem cells
**Details**:
```yaml
program: IPF program
purpose: Pharmacological regenerative treatment for Idiopathic Pulmonary Fibrosis (IPF) targeting senescent lung stem cells
grant_organization: California Institute for Regenerative Medicine (CIRM)
```

### funding
**Amount**: $40 million USD
**Amount (Numeric)**: 40000000
**Funding Date**: 2024-04-22
**Source**: Khosla Ventures, Ahren Innovation Capital (co-leads)
**Funding Type**: Series A
**Description**: Series A financing round to advance clinical development of RLS-1496 and other therapies targeting senescent cells in pulmonary diseases
**Details**:
```yaml
investors:
  - Khosla Ventures
  - Ahren Innovation Capital
  - Hevolution
  - R42
  - Modi Ventures
  - Cerigo Investments
  - Shanda Group
  - Refactor Capital
  - LongeVC
  - Italian Angels for Growth (IAG)
  - Beiersdorf AG (via Oscar & Paul corporate venture fund)
use_of_funds: Advance clinical development of RLS-1496 and other therapies targeting senescent cells in pulmonary diseases
lead_investors:
  - Khosla Ventures
  - Ahren Innovation Capital
```

### funding
**Amount**: $12 million USD
**Amount (Numeric)**: 12000000
**Funding Date**: 2020-12-03
**Source**: Khosla Ventures (lead)
**Funding Type**: Seed
**Description**: Seed financing round to advance respiratory disease candidates and expand scientific team
**Details**:
```yaml
investors:
  - Khosla Ventures
  - Longevity Fund
  - Refactor Capital
  - Shanda Group
use_of_funds: Advance respiratory disease candidates and expand scientific team
lead_investor: Khosla Ventures
```

## Events

### Awarded $1.45 million grant from California Institute for Regenerative Medicine (CIRM)
**Date**: 2023-02-06
**Type**: Grant Award
**Description**: Awarded $1.45 million grant from California Institute for Regenerative Medicine (CIRM) for pharmacological regenerative treatment of Idiopathic Pulmonary Fibrosis (IPF) targeting senescent lung stem cells
**Details**:
```yaml
amount: $1.45 million
organization: CIRM
```

### Announced nomination of first-in-class disease-modifying candidate RLS-1496 in dermatology at LSX World Congress 2023
**Date**: 2023-05-01
**Type**: Product Announcement
**Description**: Announced nomination of first-in-class disease-modifying candidate RLS-1496 in dermatology at LSX World Congress 2023
**Details**:
```yaml
event: LSX World Congress 2023
```

### Closed $40 million Series A financing round
**Date**: 2024-04-22
**Type**: Funding
**Description**: Closed $40 million Series A financing round led by Khosla Ventures and Ahren Innovation Capital
**Details**:
```yaml
amount: $40 million
```

### Announced multi-year strategic partnership with Beiersdorf AG
**Date**: 2024-04-23
**Type**: Partnership
**Description**: Announced multi-year strategic partnership with Beiersdorf AG to develop innovative skin care products addressing cellular aging. Beiersdorf also became strategic investor through Series A round
**Details**:
```yaml
partner: Beiersdorf AG
```

### Announced European expansion with opening of European headquarters in Milan, Italy
**Date**: 2024-10-01
**Type**: Expansion
**Description**: Announced European expansion with opening of European headquarters and clinical operations in Milan, Italy, ahead of first clinical trial. Expansion supported by additional investments from CDP Venture Capital and other new investors.
**Details**:
```yaml
purpose: Prepare for first clinical trial of RLS-1496 in Europe
location: Milan, Italy
investors:
  - CDP Venture Capital
  - Other new investors
```

### First patient dosed in Phase 1 clinical trial of RLS-1496
**Date**: 2025-05-01
**Type**: Clinical Milestone
**Description**: First patient dosed in Phase 1 clinical trial of RLS-1496, marking the first GPX4 modulator targeting pathologic senescent cells to enter human clinical trials
**Details**:
```yaml
significance: First-in-class milestone for GPX4 modulator senolytics
```

### FDA cleared IND application for Phase 1b/2a clinical trial of RLS-1496 in actinic keratosis
**Date**: 2025-09-01
**Type**: Regulatory Milestone
**Description**: FDA cleared IND application for Phase 1b/2a clinical trial of RLS-1496 in actinic keratosis
**Details**:
```yaml
significance: Expanded clinical development program with second indication
```

### Announced strategic partnership with SVAX
**Date**: 2025-11-01
**Type**: Partnership
**Description**: Announced strategic partnership with SVAX to advance RLS-1946 through Phase 2 clinical trials in Saudi Arabia and Dubai
**Details**:
```yaml
event: FII Week in Riyadh
partner: SVAX
```

## Partnerships

### strategic
**Date**: 2025-11-01
**Focus**: Clinical development of RLS-1946 for pulmonary diseases
**Description**: Strategic partnership to advance RLS-1946 through Phase 2 clinical trials in the Kingdom of Saudi Arabia and the Emirate of Dubai. Partnership announced during FII Week in Riyadh.
**Partner Organizations**:
- SVAX (partner)
  - Strategic partner for Phase 2 clinical trials in Middle East
**Details**:
```yaml
location:
  - Saudi Arabia
  - Dubai
clinical_phase: Phase 2
announcement_event: FII Week in Riyadh
```

### strategic
**Date**: 2024-04-23
**Focus**: Skin care products targeting cellular aging
**Description**: Multi-year strategic partnership to develop innovative skin care products addressing the effects of cellular aging. Partnership includes exploration of novel compounds from Rubedo's program targeting cellular aging for use in cosmetic products. Beiersdorf also became a strategic investor, participating in Rubedo's Series A financing round through its corporate venture fund Oscar & Paul.
**Partner Organizations**:
- Beiersdorf AG (partner)
  - Strategic partner and investor for skin care product development
**Details**:
```yaml
duration: Multi-year
venture_fund: Oscar & Paul
strategic_investment: true
```
